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Viruses depend upon the host cell for manufacturing components
of progeny virions. To mitigate the inextricable dependence on
host cell protein synthesis, viruses can modulate protein synthesis
through a variety of mechanisms. We report that the viral protein
kinase (vPK) encoded by open reading frame 36 (ORF36) of Kaposi’s
sarcoma-associated herpesvirus (KSHV) enhances protein synthesis
by mimicking the function of the cellular protein S6 kinase (S6KB1).
Similar to S6KB1, vPK phosphorylates the ribosomal S6 protein and
up-regulates global protein synthesis. vPK also augments cellular
proliferation and anchorage-independent growth. Furthermore,
we report that both vPK and S6KB1 phosphorylate the enzyme
6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 2 (PFKFB2) and
that both kinases promote endothelial capillary tubule formation.
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Protein kinases (PKs) phosphorylate cellular proteins and altersubstrate localization, enzymatic activity, and protein interac-
tions, thereby affecting signal transduction and global cellular
function. The human genome encodes ∼500 PKs that modify as
many as 30% of all cellular proteins (1). One vital serine/threonine
kinase, the mammalian target of rapamycin (mTOR), integrates
cellular demands, such as nutrient availability and environmental
stress, and tightly controls protein biosynthesis via phosphoryla-
tion of a cascade of effectors (2). To facilitate protein synthesis,
mTOR inhibits the repressor binding protein (4EBP), which nor-
mally sequesters eukaryotic initiation factor 4E (eIF4E), and pre-
vents cap-dependent protein synthesis. Cap-dependent translation
occurs once eIF4E binds the 5′ m7-guanosine cap of eukaryotic
mRNAs. Concurrently, mTOR also phosphorylates ribosomal
protein S6 kinase (S6KB1), which in turn activates protein syn-
thesis by phosphorylating tandem serines on the ribosomal S6
protein, a component of the 40S ribosome (2).
In addition to S6, other S6KB1 targets promote cellular
protein synthesis (3). For instance, S6KB1 activates eIF4B, an
RNA-binding protein that facilitates the binding of mRNA
to 40S preinitiation complexes (4). Moreover, S6KB1 is also
known to regulate MDM2, a ubiquitin ligase responsible for
degrading p53, thus preventing DNA damage-induced cell
cycle arrest or apoptosis (5). By modulating its broad reper-
toire of targets, S6KB1 plays a key role in regulating the fun-
damental cellular responses to energy status, cell survival, and
proliferation.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is linked to
Kaposi’s sarcoma (KS), primary effusion lymphoma, and multi-
centric Castleman’s disease. KS is a tumor driven by the pro-
liferation of KSHV-infected endothelial cells whereas the latter
are two B-cell lymphoproliferative diseases. The KSHV genome
encodes several proteins that broadly alter the cellular signaling
milieu and consequently impact survival and proliferation of
infected cells. For example, KSHV K1 modulates B-cell receptor-
mediated signaling and KSHV vFLIP inhibits apoptosis (6).
KSHV also encodes two kinases: ORF21, a homolog of cellular
thymidine kinase, and a viral protein kinase (vPK) encoded by
ORF36. vPK is known to be incorporated into the KSHV virion
and is presumed to be released into the host cell cytoplasm im-
mediately after entry (7, 8). The phosphorylation targets of vPK
include the cellular proteins c-Jun N-terminal kinase (JNK) and
the mitogen-activated kinases MKK4 andMKK7 (8), and K-bZIP,
a viral protein capable of repressing viral transcription (9). Other
vPK targets modulate the cellular response to DNA damage (10)
and are important for subverting type 1 IFN-mediated antiviral
signaling (11). This wide repertoire of targets results from vPK
localizing within both the cytoplasmic and nuclear compartments
(12). Within the KSHV genome, vPK is located within the ORF
34–37 cluster, which contains a hypoxia-inducible factor (HIF)
response element within the promoter region (13, 14). Thus, vPK
expression may be induced in hypoxic environments, independent
of lytic replication. Tamburro previously analyzed KS lesions de-
rived from KS-afflicted patients in Malawi and reported that 59%
of KS biopsies have detectable vPK mRNA expression (15).
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In silico structural modeling of KSHV vPK revealed similari-
ties between vPK and S6KB1. Our studies reveal that vPK
mimics S6KB1, sharing several common substrate targets and
modulating some similar cellular pathways.
Results
vPK Bears Structural Similarity to Human S6KB1. The fold recogni-
tion server HHpred (16) was used to identify suitable templates
for modeling structures of KSHV vPK. All top 100 hits from
HHpred were kinases, with most hits belonging to the serine-
threonine protein kinase family. Among these hits, one of the
significant (E value < 1.0E-41) similarities was to S6KB1, also
known as human p70 ribosomal S6 kinase (p70S6K), in addition
to other S6 kinases as well. We used the MODELLER package
and sequence alignment from HHpred to predict structures for
vPK (17). Three structures of vPK were generated using each of
the three structures of S6KB1 (derived using S6KB1 NCBI ac-
cession number NM_003161) available in the Protein Data Bank
(PDB) database. Two of the crystal structures were of different
unphosphorylated states of S6KB1 (PDB ID codes 3A60 and
3A61), and one was of the partially activated phosphorylated
state of S6KB1 (PDB ID code 3A62) (18). The structural regions
used as templates comprised residues 85–357 of human S6KB1,
against which we modeled residues 78–369 of vPK. Over this
region, vPK had four loop insertions 16, 6, 10, and 27 residues in
length, and two loop deletions 8 and 5 residues in length, along
with five 1- to 2-residue-long indels. We verified the sequence-
structure compatibility of the model of vPK based on PDB ID
code 3A62 (with the three longest inserted loops removed) using
the Verify3D Structure Evaluation Server (19).
The model of vPK based on the partially activated state of S6KB1
is rendered in spheres in Fig. 1A (18). The three longest inserted
loops are not shown because the loop structure cannot be predicted
reliably. Residues highly conserved between S6KB1 and vPK are
colored yellow, and the remainder is colored teal. Most of the
conserved residues between the two kinases occur in three motifs
that cross the active site pocket. The first motif—KrLGRGaFG
(uppercase residues are conserved and in yellow)—consists of
residues K88 to G96. The second and third motifs—DvsPDNI and
LTDFG—consist of residues D201 to I207 and L223 to G227.
Visible residues in these motifs are labeled in Fig. 1A. Compu-
tational modeling of vPK based on a partially activated S6KB1
identified potential functional residues of vPK.
The K123 residue of S6KB1 is involved in ATP binding and is
critical for kinase activity. The corresponding residue in vPK was
found to be at K108, previously reported to also be essential for
ATP binding (8). We found that the K108A mutant of vPK
abolished S6 phosphorylation, further highlighting the structural
and functional similarity of vPK and S6KB1 (Fig. S1).
Kinase Profiling Indicates Overlapping Specificity of KSHV vPK and
S6KB1. The structural similarities between vPK and S6KB1 high-
lighted by computational modeling predict an overlap in sub-
strate specificity of the two kinases. We used kinase substrate
profiling (Fig. 1B) to identify peptides preferentially phosphory-
lated by these kinases. Among the >1,300 peptides on our peptide
grid, vPK and S6KB1 respectively phosphorylated 80 and 77
peptides, with 24 common peptide targets (Fig. 1C). Among
these peptides was S6, a component of the 40S ribosome
complex, and the primary target of S6KB1. Peptides mapping
to the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,
6-bisphosphatase (PFK2/FBPase or PFKFB2) were also phos-
phorylated by both vPK and S6KB1. PFKFB2, normally regulated
by PI3K-dependent signaling (20), controls the steady-state levels
of fructose-2, 6-bisphosphate, a glycolysis intermediate. We also
identified many peptide sequences that are phosphorylated
by cellular S6KB1 that were not previously reported in the
literature.
Scanned images of each slide were scored for phosphorylation
above background, and the intensity of each spot was measured.
Intensities were plotted as seen in Fig. 1D, with vPK and S6KB1
along the x and y axes, respectively. The scattered intensity data
points formed four distinct groups: A large number of peptides
(840) were not phosphorylated by either kinase. Every other
given peptide spot was either singly phosphorylated (termed single
positives) by either vPK (56 peptides) or S6KB1 (53 peptides), or
phosphorylated by both (double positives, 24 peptides). Fisher’s
exact test was applied to determine whether the number of double
positives was enriched, given the number of single positive and
negative spots. We found a significant enrichment for double pos-
itives (odds ratio 6.8; P < 1E-9), indicating that both vPK and
S6KB1 share a common set of target substrates, thus supporting
their underlying structural similarities.
S6 Is a Verified vPK Target Substrate.Using classical in vitro kinase
assays, we found that recombinant vPK and S6KB1 both efficiently
phosphorylate a synthetic S6 peptide to similar levels, confirming
our substrate peptide profiling data (Fig. 2A). Addition of DG2, a
selective S6KB1 inhibitor, ablated phosphotransferase activity of
both S6KB1 and vPK (21, 22). DG2 was designed to selectively
bind the active site of S6KB1; thus, the ability of DG2 to inhibit
vPK to levels similar to S6KB1 confirmed the similarity in active
sites of these kinases (Fig. 2B). In contrast, neither SP-600125
(JNK inhibitor) nor MLN-8237 (aurora A inhibitor) impacted
phosphorylation of S6 by either kinase (Fig. 2B).
Fig. 1. KSHV vPK displays limited homology to cellular S6KB1. (A) In silico
model of vPK based on the partially activated state of S6KB1 is rendered in
spheres. Residues highly conserved between S6KB1 and vPK are colored yel-
low, and the rest are teal. Most of the conserved residues between the two
kinases occur in three motifs that cross the active site pocket. The first motif—
KrLGRGaFG (uppercase residues are conserved and in yellow)—consists of
residues K88 to G96. The second and third motifs—DvsPDNI and LTDFG—
consist of residues D201 to I207 and L223 to G227. (B) A PepChip array was
used to identify targets of both vPK and S6KB1. Recombinant kinases were
incubated with radiolabeled ATP on a glass slide arrayed with >1,000 kinase
substrate peptides. (C) Twenty-four peptides are phosphorylated by both vPK
and S6KB1. vPK and S6KB1 were found to uniquely phosphorylate an addi-
tional 56 and 53 peptides, respectively. (D) Scatter plot analysis of spot in-
tensities of peptides phosphorylated either uniquely by vPK (y axis; closed
circles) or S6KB1 (x axis; closed squares), dually phosphorylated by both (closed
triangles), or spots phosphorylated by neither kinase (open circles).









To confirm the functional similarity of these proteins, eukaryotic
expression vectors for vPK and matched vector control were
transiently transfected into 293 cells for 36 h and either placed in
normal media or serum-starved for 12 h. Lysates prepared from
harvested cells were subjected to immunoblotting. Levels of
phospho-S6 were significantly higher in vPK-transfected cells
compared with vector controls (Fig. 2C, Left). vPK sustained
phospho-S6 levels even in serum-starved cells (Fig. 2C, Right).
We replicated our studies by stably expressing either vPK,
S6KB1, or matched empty vector controls in immortalized
human umbilical vein endothelial cells (HUVECs). Because
Kaposi’s sarcoma is an angioproliferative tumor primarily driven
by endothelial cells, HUVECs represent a biologically relevant
cell type to test the function of vPK. Immunoblot analyses of
harvested log phase cells showed elevated phospho-S6 in both
vPK- and S6K-expressing HUVEC stable cells, compared with
empty vector (Fig. 2D). Further confirming the peptide profiling
data, we found that both vPK and S6KB1 induce phosphorylation
of PFKFB2, an enzyme responsible for enhancing glycolysis. In-
terestingly, vPK also increased phosphorylation of the eukaryotic
initiation factor 4E (eIF4E), the cap recognition protein respon-
sible for binding to the m7-guanosine cap of eukaryotic messenger
RNAs. Normally, eIF4E is sequestered via association with 4E
binding protein (4EBP1); however, mTOR-dependent hyper-
phosphorylation of 4EBP1 releases eIF4E, which subsequently
promotes translation initiation (23). vPK was also found to phos-
phorylate the S6KB1 target MDM2, further accentuating the high
degree of substrate overlap of these two kinases (5). Despite con-
verging substrates, both kinases also have a discrete repertoire of
targets. For example, S6KB1, but not vPK, phosphorylates eIF4B,
an ATP-dependent helicase essential for protein translation, and, as
previously reported, vPK phosphorylates the mitogen-activated ki-
nase JNK, whereas S6KB1 does not (8). We transfected HUVECs
with nontargeting (NT) siRNA, S6KB1 siRNA, or vPK-specific
siRNA. Twenty-four hours later, the cells were infected with KSHV
as previously described (24). Cells were harvested 1 h postinfection
(HPI), and lysates were subjected to SDS/PAGE and immuno-
blotting. We found that KSHV infection induces phospho-S6 and
phospho-JNK in HUVECs (Fig. S2). Furthermore, prior S6KB1
knockdown does not substantially decrease phospho-S6 in the
context of KSHV infection (Fig. S2), suggesting that vPK activates
S6 in an S6KB1-independent manner. vPK siRNA does not reduce
phospho-S6, consistent with our current understanding that vPK is a
tegument protein that is packaged within the tegument layer of the
virion and released into the cytoplasm after virion infection (8).
KSHV vPK Enhances Global Protein Synthesis. To determine whether
increased S6 phosphorylation by vPK corresponds with alteration
of global protein synthesis, we measured incorporation of radio-
active methionine and cysteine in 293 cells expressing vPK, S6KB1,
or vector. As expected, ectopically expressed S6KB1 enhanced
protein synthesis compared with vector. Interestingly, vPK also
increased the basal levels of global protein synthesis compared
with vector (Fig. 2E). We also measured basal protein synthesis
Fig. 2. KSHV vPK phosphorylates several S6KB1
substrates. (A) An in vitro kinase assay was per-
formed with recombinant vPK and S6K using a syn-
thetic S6 substrate. Data are representative of four
independent experiments; error bars denote SEM.
(B) Impact of S6KB1-specific and nonspecific kinase
inhibitors on recombinant vPK and S6KB1 phosphor-
ylation of S6 peptide substrate in an in vitro kinase
assay. Data are representative of three independent
experiments; error bars are ±SEM. (C) Ectopic expres-
sion of vPK in 293 cells increases phosphorylated levels
of S6. Total S6 and tubulin are shown as loading
controls. Construct expression is verified using a vPK-
specific antibody. These images are representative of
three independent experiments. ℗, phospho. (D) Sta-
ble HUVECs were first plated in normal media; sub-
sequently, serum was withdrawn for 16 h, and
immunoblots were performed with harvested lysates
for the indicated phosphorylated and corresponding
total proteins. Tubulin is shown as loading control.
These images are representative of four independent
experiments. (E) Metabolic labeling of de novo pro-
tein synthesis using 35S-labeled methionine and
cysteine was quantified in 293 cells transiently
transfected with vector, vPK, or S6KB1. Counts are
normalized to total protein content. Data are rep-
resentative of three independent experiments; er-
ror bars are ±SEM. (F) Metabolic labeling of de novo
protein synthesis using 35S-labeled methionine and
cysteine was quantified in stable HUVECs expressing
vPK, S6KB1, or matched vector control. Counts are
normalized to total protein content. Data are repre-
sentative of three independent experiments; error
bars are ±SEM, **P < 0.01, ****P < 0.0001.
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in stable HUVECs expressing either vPK or S6KB1 and noted a
statistically significant elevation in protein synthesis over vector
control, when either vPK or S6KB1 was expressed (Fig. 2F).
KSHV vPK Enhances Cellular Proliferation. To determine whether
vPK-mediated enhancement of S6 phosphorylation impacts the
physiology of the host cell, we assayed cellular metabolic rates.
Stable HUVECs were transfected with either scrambled or vPK-
specific siRNA for 24 h and expression after knockdown was
confirmed by immunoblot (Fig. S3). Equivalent numbers of cells
were seeded onto 96-well plates, and cellular proliferation was
quantified using Cell Titer Aqueous One MTS reagent. By
comparing the absorbance values of each stable cell line over a
course of 72 h, we found that vPK-expressing HUVECs have a
higher absorbance compared with vector cells. However, when
transfected with vPK-specific siRNA, cellular proliferation rates
of HUVEC-vPK were reduced to those of vector (Fig. 3A), which
indicates that a vPK-mediated increase in S6 phosphorylation may
translate into accelerated cell proliferation rates.
S6 phosphorylation is tightly regulated by the upstream kinase,
S6KB1, which itself is regulated by the PI3K/AKT/mTOR sig-
naling pathway. mTOR activity can be subdued either by in-
hibition of upstream regulatory kinases, such as PI3K using the
reversible inhibitor LY294002, or by treatment with rapamycin, a
macrolide that directly binds to and inhibits the mTOR complex.
Diminished S6 phosphorylation (particularly at S235, S236) is a
prognostic indicator of rapamycin’s efficacy (25) and a signature of
S6KB1 inhibition. We have previously shown that the PI3K/AKT/
mTOR pathway is critical for the survival of KSHV-infected cells
(25, 26). We treated transfected 293 cells with 10 nM LY294002 or
rapamycin, or the respective vehicle, for 1 h, after which cells were
harvested and immunoblotting was performed with the lysates.
Interestingly, we found that after LY294002 and rapamycin
treatment, S6 phosphorylation was sustained in vPK-expressing
cells and was at a higher level than the vector- and S6K-trans-
fected cells, where phospho-S6 was diminished (Fig. 3B). We also
treated stable HUVECs with increasing doses of rapamycin (10
and 50 nM) for 1 h and performed immunoblots. Similar to
transfected 293 cells, S6 phosphorylation after rapamycin treat-
ment was still higher in vPK-expressing stable HUVECs (Fig. 3C),
compared with vector- and S6KB1-expressing HUVECs. These
observations indicate that, despite mTORC1 inhibition, vPK can
sustain phosphorylation of S6.
Next, we transfected stable vPK-expressing 293 cells with either
scrambled or a pool of both mTOR- and Raptor-specific siRNAs
(denoted “mT”) and analyzed phospho-S6 levels (Fig. 3D). A
reduction in phospho-S6 levels was observed in mTOR-regulated
S6KB1 (Thr389) concurrent with mTOR/Raptor knockdown.
vPK-expressing 293 cells had higher levels of phospho-S6 even in
the context of mTOR/Raptor knockdown, confirming that vPK can
sustain phosphorylation of S6 even when mTORC1 expression
is depleted.
To dissect the role of vPK in the viral life cycle, we used the
latent KSHV-infected iSLK cell line, which can be induced into
lytic replication by doxycycline-dependent expression of the
replication and transcription activator (RTA) (27). This cell line
fluoresces green when latently infected with KSHV; productive
viral replication leads to RFP expression under control of a lytic
promoter. iSLK.219 cells were transfected with either non-
targeting (NT) or vPK-directed siRNA, with simultaneous
doxycycline-mediated reactivation. Cells transfected with NT siRNA
had maximal vPK expression within 48 h after reactivation,
with a concurrent elevation in S6 phosphorylation (Fig. 3E).
We found that after vPK-specific siRNA knocked down vPK
expression, S6 phosphorylation was greatly reduced. To gauge
the degree of infectivity of newly synthesized virions, super-
natants from latent and reactivated iSLK.219 cells containing
either vPK-specific or NS siRNA were collected, clarified, and
applied for 48 h to naive 293 cells; infection was monitored by
fluorescence microscopy. Compared with virus derived from NT
siRNA-transfected cells, KSHV derived from vPK-knockdown
cells was significantly attenuated, indicated by the small number
of GFP+ 293 cells (Fig. 3F).
vPK Expression Augments Anchorage Independence. To investigate
whether increases in S6 phosphorylation and protein synthesis
functionally impact the growth of vPK-expressing cells, we per-
formed a soft agar assay using stable Rat1 fibroblasts. Five hundred
stable cells were suspended in agarose-containing media. Three
weeks later, colonies were stained with crystal violet and counted in a
blinded manner. Rat1 fibroblasts expressing empty vector or GFP
(negative control) formed very few colonies whereas S6KB1 expres-
sion modestly increased the number of colonies. In contrast, vPK-
expressing cells had a significantly higher number of colonies. Simian
virus 40 (SV40) T antigen was used as a positive control (Fig. 4A).
vPK Induces Endothelial Tubule Formation in HUVECs. Endothelial
tubule formation assays measure the ability of endothelial cells
Fig. 3. KSHV vPK enhances cellular proliferation. (A) Stable HUVECs trans-
fected with indicated siRNAs were plated in a 96-well plate, and their basal
metabolic rate was measured 72 h afterward using the Cell Titer Aqueous
One Assay. Data are representative of three independent experiments; error
bars are ±SEM, ****P < 0.001. NTC, nontargeting control. (B) Immunoblot
analyses of indicated proteins with lysates prepared from 293 cells tran-
siently transfected with empty vector, vPK, or S6KB1 and then treated with
either LY294002 or rapamycin (10 nM), each for 1 h. Transgene expression
was confirmed using vPK- and FLAG-specific antibodies. Tubulin is shown as
a loading control. Images represent one of three independent experiments.
(C ) Stable HUVECs were treated with increasing doses of rapamycin (10,
50 nM) for 1 h, and harvested lysates were subject to immunoblotting with
indicated phospho-specific and total antibodies. Although phospho-S6
remains elevated after rapamycin treatment in HUVEC-vPK, it is diminished in
vector- and S6KB1-expressing HUVECs. Images are representative of three in-
dependent experiments. (D) Stable 293 cells were transfected with indicated
siRNAs for 48 h, and immunoblots were performed after 12-h serum with-
drawal. mT, pooled Raptor- and mTOR-specific siRNA; Scr, scrambled. (E) Im-
munoblot analysis of both latent (No Dox) and reactivated (Dox) iSLK.219 cells
transfected with either vPK-directed or a nonspecific (NS) siRNA. Representa-
tive of four independent experiments. (F) Infectivity of 293 cells infected with
KSHV derived from the experiment described in E; **** P < 0.0001.









to induce tubule formation in vitro (28). Stable HUVECs
expressing either vPK or empty vector were used. Growth factor-
reduced Matrigel was used to mitigate any cytokines and growth
factors contained in standard Matrigel. Stable HUVEC-
expressing empty vector formed small tubules 4 h after place-
ment on Matrigel, with maximal tubular networks formed within
12 h. Tubule formation was accelerated in vPK-expressing
HUVECs, with intricate tubular networks forming as early as 4 h
after plating (Fig. 4B; quantified in Fig. 4C, Left). By 8 h, extensive
tubular matrices could be seen in vPK- and S6KB1-expressing
HUVECs (Fig. 4C, Right). At all time points analyzed, tubule
branching was significantly higher in vPK-expressing cells, com-
pared with EV- and S6KB1-expressing HUVECs. S6KB1-
expressing HUVECs showed increased tubule formation at and
after 8 h compared with the vector-control HUVECs (Fig. 4C).
These observations suggest that protein synthesis induced by
vPK may drive angiogenic remodeling in endothelial cells. Al-
ternatively, it is also possible that vPK and S6KB1 modulate
expression and/or activation of proteins that impact endothelial
cell remodeling and angiogenesis.
Discussion
Herpesviruses establish lifelong latency in the host, with sporadic
bouts of viral reactivation and replication. These viruses com-
mandeer host cell machinery to synthesize viral proteins needed
for successful replication. For example, UL13 and UL97,
orthologous kinases encoded by herpes simplex type I (HSV1) and
human cytomegalovirus (HCMV), respectively, are functionally
similar to the cellular kinase CDC2/CDK1 and phosphorylate
several cellular functional targets of cyclin-dependent kinases,
including elongation factor 1δ (EF1δ) (29) and pRB (30).
Herpesviral kinases are also known to phosphorylate several
different members of the cellular DNA damage response
pathway. Notably, the regulatory protein TIP60 is targeted by
herpesvirus kinases and is known to be essential for efficient
herpesvirus replication (10).
Like other herpesviruses, KSHV depends on the host for
replication, propagation, and dissemination. Using in silico struc-
tural modeling approaches, we discovered that vPK displays
limited structural similarity to the cellular S6KB1 (also known
as p70S6K or RPS6KB1) protein. Given that vPK homologs
are present in all human herpesviruses and that it is predicted to
be a core protein in the common ancestor to the Herpesviridae
(31), acquisition of the vPK ancestral protein possibly occurred
more than 400 million y ago. S6KB1 expression is known to en-
hance protein synthesis and is itself tightly controlled via phos-
phorylation by mTORC1. We hypothesize that vPK’s ability to
mimic S6KB1 is advantageous for the virus because it provides a
mechanism for activating protein synthesis despite host antiviral
signaling, which normally down-regulates protein synthesis as a
defensive strategy.
We identified overlapping and unique cellular targets of both
vPK and S6KB1 using a peptide array. We identified S6 as a
significant target of vPK-mediated phosphorylation. As a com-
ponent of the eukaryotic 40S ribosome, S6 is phosphorylated at
tandem serines in an mTOR-dependent manner by its cognate
kinase S6KB1. Phosphorylated S6 is a well-established signature
of active protein translation of capped mRNAs. Using an in vitro
kinase assay, we found that vPK phosphorylates S6 peptide at the
same residues phosphorylated by S6KB1 (S235, S236), which
denotes activation of protein translation. Moreover, DG2, a
S6KB1-specific kinase inhibitor (21, 22), abolished phospho-
transferase activity of both S6KB1 and vPK, underscoring the
similarity of the active sites of these two kinases. Through ectopic
vPK expression in both epithelial (293) and endothelial (HUVEC)
cells, we confirmed that vPK phosphorylates S6, the furthest
downstream effector of PI3K/AKT/mTOR signaling. Overall, our
data suggest that there are a set of common targets of vPK and
S6KB1. Additionally, vPK can phosphorylate proteins that S6K
cannot, thereby expanding the repertoire of cellular proteins that
vPK can target.
We report that levels of phospho-S6 are reduced when vPK
expression was depleted during lytic reactivation. Moreover, vi-
rions generated from vPK-depleted cells were less infectious,
compared with nonspecific siRNA-transfected cells. These ob-
servations suggest that activation of cellular pathways (e.g., protein
synthesis) by vPK is important for virion production during the
replicative life cycle.
Furthermore, vPK-mediated S6 phosphorylation translates
into enhanced global protein synthesis in cells of both epithelial
and endothelial origin. A recent report used quantitative phos-
phoproteomics to identify strictly nuclear targets of BGLF4, the
Epstein–Barr virus homolog of KSHV vPK. BGLF4 was found to
affect the cellular phosphoprotein milieu, including the phos-
phorylation of mitotic kinases (32).
Fig. 4. KSHV vPK augments tubule formation. (A) Rat1 fibroblasts stably
expressing the indicated transgenes were plated in soft agar for 3 wk. Col-
onies were stained with crystal violet and quantified to measure anchorage
independence. Data are representative of four independent experiments;
error bars are ±SEM; ****P < 0.0001. (B) When placed in growth factor-re-
duced Matrigel, vPK-stable HUVECs form tubular networks within 4 h. Also
shown are EV- and S6KB1-expressing cells. (C) Significantly increased
branching was observed at 4 h (Left) and 8 h (Right) in vPK-expressing
HUVECs, compared with EV- and S6KB1-HUVEC. Tubule formation data are
representative of three independent experiments. (D) Proposed model for
vPK’s mechanism of action.
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vPK was also found to phosphorylate an essential regulator of
glycolysis, PFKFB2, which we found is also a direct S6KB1 tar-
get. Glycolysis is a frequent bioenergetic adaptation of cancer
cells, both in aerobic conditions and in hypoxic environments
unfavorable for oxidative phosphorylation. Notably, vPK is in-
duced by hypoxia (13, 14), and, furthermore, KSHV is known to
up-regulate glycolysis in both lytic and latent conditions (33, 34).
Thus, vPK may modulate the induction of the glycolytic pheno-
type. We found that vPK-expressing HUVECs established a
larger number of tubule networks compared with control cells at
all time points. A recent report underscores the importance of
glycolysis for driving capillary endothelial tubule formation in vivo
(35). Since PFKFB2 was found to be a target for phosphorylation
by vPK and S6KB1, it is likely that the mechanism for tubule
formation by these two kinases is similar and may be independent
of their impact on protein synthesis. Nonetheless, vPK-induced
enhancement of tubule formation suggests that vPK may play a
role in the angiogenesis apparent in Kaposi’s sarcoma.
We propose a model wherein vPK circumvents regulatory
control by upstream kinases and activates the ribosomal protein
S6, the furthest downstream effector of PI3K/AKT/mTOR sig-
naling (Fig. 4D). By directly phosphorylating S6, vPK abolishes
the need for S6KB1-dependent phosphorylation, thus preempting
inhibitory signaling that may result from growth factor withdrawal,
nutrient scarcity, or active antiviral signaling. In conclusion,
based on our in silico findings and biochemical data, we pro-
pose that vPK mimics S6KB1 function and, as such, induces
infected cells to up-regulate protein synthesis, proliferate, and
vascularize, despite upstream inhibitory signals. These findings
bear significant implications for KSHV-associated malignancies
including Kaposi’s sarcoma.
Materials and Methods
Human embryonic kidney-293 (293) cells were cultured in DMEM supple-
mented with 10% (vol/vol) heat-inactivated FBS, 100 IU/mL penicillin G and
100 μg/mL streptomycin (P/S), and 2 mM L-glutamate. Primary human um-
bilical vein endothelial cells were cultured in endothelial cell growth me-
dium supplemented with 10% heat-inactivated FBS, as previously described
(28, 36). Rat1 fibroblasts were cultured in DMEM with 10% heat-inactivated
calf serum, P/S, and 2 mM L-glutamate. The iSLK.219 clone 10 cells were
cultured as previously described (27). Additional methods are described in SI
Materials and Methods.
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